Advent International, a private equity firm based in Boston, Massachusetts, is considering a buyout deal for drugmaker Swedish Orphan Biovitrum.
Advent has approached other buyout firms including Permira in an attempt to lead a consortium for the acquisition of the Swedish biotech firm.
Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.
It is also weighing to bring in sovereign wealth funds for the bid. The talks are at an early stage, and it is not yet clear that they will ultimately lead to a deal, according to the people.
Source: Seeking Alpha
Can’t stop reading? Read more
Top private equity news of the week
Top private equity news of the week Soho House, the global private members’ club and hotel group,...
Audax turns to Blackstone as Justrite seeks $700m private credit lifeline
Audax turns to Blackstone as Justrite seeks $700m private credit lifeline Audax Private Equity is...
Mitsubishi takes stake in RRJ-backed Fullerton Health to fuel Southeast Asia growth
Mitsubishi takes stake in RRJ-backed Fullerton Health to fuel Southeast Asia growth Mitsubishi...